16 March 2021Big PharmaJian Siang Poh and Angus Fairbairn
Patent filing strategies for pharma startups
The development of any new drug requires considerable investment of time and resources into extensive research and development (R&D), even in the hit to lead and pre-clinical stages. While larger pharmaceutical companies with deep pockets are used to managing the costs associated with drug development, pharmaceutical startups and small and medium-sized enterprises (SMEs) may encounter more difficulty in balancing their budgets, particularly when it comes to allocating funds for generating patent portfolios.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 April 2022 The ‘joint applicants’ approach to PCT applications would provide an elegant solution to issues of who is entitled to priority claims in PCT applications, suggests Chiara Banas of EIP.
31 May 2013 The definition of what constitutes a co-pending patent filing in Europe has recently been rewritten to include
patent applications from within the same patent family. Jane Wainwright of Potter Clarkson investigates
the decisions leading to this change.